• FirefoxInstall the new Firefox »
  •  Dow Up0.61% Nasdaq Up0.57%

    MannKind Corp. (MNKD)

    6.70 Up 0.18(2.76%) 2:20PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    MannKind Corp.
    28903 North Avenue Paine
    Valencia, CA 91355
    United States - Map
    Phone: 661-775-5300
    Website: http://www.mannkindcorp.com

    Index Membership:N/A
    Full Time Employees:265

    Business Summary 

    MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate is AFREZZA inhalation powder, an insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company is also developing MedTone and Dreamboat inhaler devices. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on MannKind Corp.

    Corporate Governance 
    MannKind Corp.’s ISS Governance QuickScore as of Feb 1, 2015 is 9. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 3; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Alfred E. Mann , 89
    Founder and Exec. Chairman
    Mr. Hakan S. Edstrom B.Sc., M.B.A., 65
    Chief Exec. Officer, Pres and Director
    Mr. Matthew J. Pfeffer CPA, 57
    Chief Financial Officer, Principal Accounting Officer and Corp. VP
    Dr. Juergen A. Martens Ph.D., 59
    Chief Operating Officer
    Dr. David B. Thomson Ph.D., J.D., 48
    Corp. VP, Gen. Counsel and Corp. Sec.
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders